How to ensure clinical trial sensitivity in psychotropic drug development: a case study.
Videla
Sebastián
S
Sust
Mariano
M
Fresquet
Anna
A
Villoria
Jesús
J
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D035061:Control Groups; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design / Q000706:statistics & numerical data*
D014151:Anti-Anxiety Agents; D015507:Drugs, Investigational; D010919:Placebos; D008140:Lorazepam